Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 1, 2011, Pages 42-49

  Koh, Yasuhiro ^a   Haim, Hillel ^a   Engelman, Alan ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELVITEGRAVIR; NEVIRAPINE; RALTEGRAVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL TYPE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; POSTANTIVIRAL EFFECT; PRIORITY JOURNAL; VIRUCIDAL ACTIVITY; VIRUS DNA CELL DNA INTERACTION;

ADENINE; ANTI-HIV AGENTS; CELL LINE; HELA CELLS; HIV-1; HUMANS; INTEGRASE INHIBITORS; PHOSPHONIC ACIDS; PYRROLIDINONES; QUINOLONES; ZIDOVUDINE;

EID: 78650670855     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01064-10     Document Type: Article

References (48)

1. Azoulay, S., M.-C. Nevers, C. Creminon, L. Heripret, J. Durant, P. Dellamonica, J. Grassi, R. Guedj, and D. Duval. 2004. Sensitive enzyme immunoassay for measuring plasma and intracellular nevirapine levels in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48:104-109.
2. Balzarini, J., A. Holy, J. Jindrich, L. Naesens, R. Snoeck, D. Schols, and E. De Clercq. 1993. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2- phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother. 37:332-338.
3. Balzarini, J., L. Naesens, S. Aquaro, T. Knispel, C. Perno, E. De Clercq, and C. Meier. 1999. Intracellular metabolism of CycloSaligenyl 3′-azido-2′,3′- dideoxythymidine monophosphate, a prodrug of 3′-azido-2′,3′-dideoxythymidine (zidovudine). Mol. Pharmacol. 56:1354-1361.
4. Bar-Magen, T., R. D. Sloan, V. H. Faltenbacher, D. A. Donahue, B. D. Kuhl, M. Oliveira, H. Xu, and M. A. Wainberg. 2009. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology 6:103.
5. Collman, R. 1992. Human immunodeficiency virus type 1 tropism for human macrophages. Pathobiology 60:213-218.
6. Craig, W. A. 1993. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J. Antimicrob. Chemother. 31(Suppl. D):149-158.
7. Daelemans, D., R. Lu, E. De Clercq, and A. Engelman. 2007. Characterization of a replication-competent, integrase-defective human immunodeficiency virus (HIV)/simian virus 40 chimera as a powerful tool for the discovery and validation of HIV integrase inhibitors. J. Virol. 81:4381-4385.
8. De Clercq, E., N. Yamamoto, R. Pauwels, M. Baba, D. Schols, H. Nakashima, J. Balzarini, Z. Debyser, B. A. Murrer, D. Schwartz, D. Thornton, G. Bridger, S. Fricker, G. Henson, M. Abrams, and D. Picker. 1992. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc. Natl. Acad. Sci. U. S. A. 89:5286-5290.
9. Drusano, G. L. 1993. Pharmacodynamics of antiretroviral chemotherapy. Infect. Control Hosp. Epidemiol. 14:530-536.
10. Espeseth, A. S., P. Felock, A. Wolfe, M. Witmer, J. Grobler, N. Anthony, M. Egbertson, J. Y. Melamed, S. Young, T. Hamill, J. L. Cole, and D. J. Hazuda. 2000. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. U. S. A. 97:11244-11249.
11. Gorry, P. R., G. Bristol, J. A. Zack, K. Ritola, R. Swanstrom, C. J. Birch, J. E. Bell, N. Bannert, K. Crawford, H. Wang, D. Schols, E. De Clercq, K. Kunstman, S. M. Wolinsky, and D. Gabuzda. 2001. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J. Virol. 75:10073-10089.
12. Gray, L., M. Roche, M. J. Churchill, J. Sterjovski, A. Ellett, P. Poumbourios, S. Sherieff, B. Wang, N. Saksena, D. F. Purcell, S. Wesselingh, A. L. Cunningham, B. J. Brew, D. Gabuzda, and P. R. Gorry. 2009. Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain. J. Virol. 83:5430-5441.
13. Grobler, J. A., P. M. Mckenna, S. Ly, K. A. Stillmock, C. M. Bahnck, R. M. Danovich, G. Dornadula, D. J. Hazuda, and M. D. Miller. 2009. HIV integrase inhibitor dissociation rates correlate with efficacy in vitro. Antivir. Ther. 14(Suppl. 1):A27.
14. Haim, H., I. Steiner, and A. Panet. 2005. Synchronized infection of cell cultures by magnetically controlled virus. J. Virol. 79:622-625.
15. Hare, S., F. Di Nunzio, A. Labeja, J. Wang, A. Engelman, and P. Cherepanov. 2009. Structural basis for functional tetramerization of lentiviral integrase. PLoS Pathog. 5:e1000515.
16. Hazuda, D. J., S. D. Young, J. P. Guare, N. J. Anthony, R. P. Gomez, J. S. Wai, J. P. Vacca, L. Handt, S. L. Motzel, H. J. Klein, G. Dornadula, R. M. Danovich, M. V. Witmer, K. A. Wilson, L. Tussey, W. A. Schleif, L. S. Gabryelski, L. Jin, M. D. Miller, D. R. Casimiro, E. A. Emini, and J. W. Shiver. 2004. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305:528-532.
17. Hightower, K., R. Wang, and M. Underwood. 2010. S/GSK1349572 demonstrates significantly slower dissociation rates than raltegravir when comparing wild type and raltegravir resistant integrase protein. International HIV & Hepatitis Virus Drug Resistance Workshop, Dubrovnik, Croatia. Antivir. Ther. 15(Suppl. 2):A16.
18. Hombrouck, A., B. Van Remoortel, M. Michiels, W. Noppe, F. Christ, A. Eneroth, B. L. Sahlberg, K. Benkestock, L. Vrang, N. G. Johansson, M. L. Barreca, L. De Luca, S. Ferro, A. Chimirri, Z. Debyser, and M. Witvrouw. 2008. Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors. Antimicrob. Agents Chemother. 52:2861-2869.
19. Hombrouck, A., A. Voet, B. Van Remoortel, C. Desadeleer, M. De Maeyer, Z. Debyser, and M. Witvrouw. 2008. Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Antimicrob. Agents Chemother. 52:2069-2078.
20. Iwamoto, M., L. A. Wenning, A. S. Petry, M. Laethem, M. De Smet, J. T. Kost, S. A. Merschman, K. M. Strohmaier, S. Ramael, K. C. Lasseter, J. A. Stone, K. M. Gottesdiener, and J. A. Wagner. 2008. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin. Pharmacol. Ther. 83:293-299.
21. Kelly, J., M. H. Beddall, D. Yu, S. R. Iyer, J. W. Marsh, and Y. Wu. 2008. Human macrophages support persistent transcription from unintegrated HIV-1 DNA. Virology 372:300-312.
22. Klibanov, O. M. 2009. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr. Opin. Invest. Drugs 10:190-200.
23. Kurth, R., and N. Bannert. 2010. Retroviruses: molecular biology, genomics and pathogenesis. Caister Academic Press, Norfolk, United Kingdom.
24. Levy, J. A. 2009. HIV pathogenesis: 25 years of progress and persistent challenges. AIDS 23:147-160.
25. Lu, R., H. Z. Ghory, and A. Engelman. 2005. Genetic analyses of conserved residues in the carboxyl terminal domain of human immunodeficiency virus type 1 integrase. J. Virol. 79:10356-10368. (Pubitemid 41098576)
26. Lu, R., A. Limon, E. Devroe, P. A. Silver, P. Cherepanov, and A. Engelman. 2004. Class II integrase mutants with changes in putative nuclear localization signals are primarily blocked at a postnuclear entry step of human immunodeficiency virus type 1 replication. J. Virol. 78:12735-12746.
27. MacKenzie, F. M., and I. M. Gould. 1993. The post-antibiotic effect. J. Antimicrob. Chemother. 32:519-537.
28. Maddon, P. J., A. G. Dalgleish, J. S. McDougal, P. R. Clapham, R. A. Weiss, and R. Axel. 1986. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47:333-348.
29. Markowitz, M., J. O. Morales-Ramirez, B. Y. Nguyen, C. M. Kovacs, R. T. Steigbigel, D. A. Cooper, R. Liporace, R. Schwartz, R. Isaacs, L. R. Gilde, L. Wenning, J. Zhao, and H. Teppler. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43:509-515.
30. McColl, D. J., and X. Chen. 2010. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res. 85:101-118.
31. Merluzzi, V. J., K. D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J. C. Wu, C. K. Shih, K. Eckner, S. Hattox, J. Adams, A. S. Rosenthal, R. Faanes, R. J. Eckner, R. A. Koup, and J. L. Sullivan. 1990. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250: 1411-1413.
32. Mitsuya, H., K. J. Weinhold, P. A. Furman, M. H. St. Clair, S. N. Lehrman, R. C. Gallo, D. Bolognesi, D. W. Barry, and S. Broder. 1985. 3′-Azido-3′- deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy- associated virus in vitro. Proc. Natl. Acad. Sci. U. S. A. 82:7096-7100.
33. Motakis, D., and M. A. Parniak. 2002. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46:1851-1856.
34. Nakajima, N., R. Lu, and A. Engelman. 2001. Human immunodeficiency virus type 1 replication in the absence of integrase-mediated DNA recombination: definition of permissive and nonpermissive T-cell lines. J. Virol. 75:7944-7955.
35. Nakata, H., M. Amano, Y. Koh, E. Kodama, G. Yang, C. M. Bailey, S. Kohgo, H. Hayakawa, M. Matsuoka, K. S. Anderson, Y. C. Cheng, and H. Mitsuya. 2007. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4′-ethynyl-2-fluoro- 2′-deoxyadenosine. Antimicrob. Agents Chemother. 51:2701-2708.
36. Pannecouque, C., W. Pluymers, B. Van Maele, V. Tetz, P. Cherepanov, E. De Clercq, M. Witvrouw, and Z. Debyser. 2002. New class of HIV integrase inhibitors that block viral replication in cell culture. Curr. Biol. 12:1169-1177.
37. Pauwels, R., K. Andries, J. Desmyter, D. Schols, M. J. Kukla, H. J. Breslin, A. Raeymaeckers, J. Van Gelder, R. Woestenborghs, J. Heykants, K. Schellekens, M. A. C. Janssen, E. De Clercq, and P. A. J. Janssen. 1990. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343:470-474. (Pubitemid 120028562)
38. Pierson, T. C., Y. Zhou, T. L. Kieffer, C. T. Ruff, C. Buck, and R. F. Siliciano. 2002. Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J. Virol. 76:8518-8531.
39. Piliero, P. J. 2004. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr. 37(Suppl. 1):S2-S12.
40. Sacha, J. B., and D. I. Watkins. 2010. Synchronous infection of SIV and HIV in vitro for virology, immunology and vaccine-related studies. Nat. Protoc. 5:239-246.
41. Sato, M., T. Motomura, H. Aramaki, T. Matsuda, M. Yamashita, Y. Ito, H. Kawakami, Y. Matsuzaki, W. Watanabe, K. Yamataka, S. Ikeda, E. Kodama, M. Matsuoka, and H. Shinkai. 2006. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem. 49:1506-1508.
42. Smith, P. F., R. DiCenzo, and G. D. Morse. 2001. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin. Pharmacokinet. 40: 893-905.
43. Summa, V., A. Petrocchi, F. Bonelli, B. Crescenzi, M. Donghi, M. Ferrara, F. Fiore, C. Gardelli, O. Gonzalez Paz, D. J. Hazuda, P. Jones, O. Kinzel, R. Laufer, E. Monteagudo, E. Muraglia, E. Nizi, F. Orvieto, P. Pace, G. Pescatore, R. Scarpelli, K. Stillmock, M. V. Witmer, and M. Rowley. 2008. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 51:5843-5855.
44. Swiggard, W. J., C. Baytop, J. J. Yu, J. Dai, C. Li, R. Schretzenmair, T.Theodosopoulos, and U. O'Doherty. 2005. Human immunodeficiency virus type 1 can establish latent infection in resting CD4′ T cells in the absence of activating stimuli. J. Virol. 79:14179-14188.
45. Tsibris, A. M., and M. S. Hirsch. 2010. Antiretroviral therapy in the clinic. J. Virol. 84:5458-5464.
46. Wang, Y. J., P. M. McKenna, R. Hrin, P. Felock, M. Lu, K. G. Jones, C. A. Coburn, J. A. Grobler, D. J. Hazuda, M. D. Miller, and M. T. Lai. 2010. Assessment of the susceptibility of mutant HIV-1 to antiviral agents. J. Virol. Methods 165: 230-237.
47. Wenning, L., B.-Y. Nguyen, X. Sun, E. Hwang, Y. Chen, H. Teppler, C. Harvey, R. Rhodes, D. Ryan, N. Azrolan, and J. Stone. 2008. Pharmacokinetic/ pharmacodynamic (PK/PD) analyses for raltegravir (RAL) in phase II and III studies in treatment experienced HIV-infected patients, abstr. O-21. 9th Int. Workshop Pharmacol. HIV Ther., New Orleans, LA. Virology Education B.V., Utrecht, Netherlands.
48. Young, S. D., S. F. Britcher, L. O. Tran, L. S. Payne, W. C. Lumma, T. A. Lyle, J. R. Huff, P. S. Anderson, D. B. Olsen, S. S. Carroll, D. J. Pettibone, J. A. O'Brien, R. G. Ball, S. K. Balani, J. H. Lin, I.-W. Chen, W. A. Schleif, V. V. Sardana, W. J. Long, V. W. Byrnes, and E. A. Emini. 1995. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39:2602-2605